tradingkey.logo
tradingkey.logo
Search

Guardant Health Inc

GH
Add to Watchlist
153.740USD
+4.520+3.03%
Close 06/29, 16:00ETQuotes delayed by 15 min
20.22BMarket Cap
LossP/E TTM

TradingKey Stock Score of Guardant Health Inc

Currency: USD Updated: 2026-06-29

Key Insights

Guardant Health Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 8 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 146.18.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking
8 / 204
Overall Ranking
47 / 4570
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Guardant Health Inc Highlights

StrengthsRisks
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 74.13% year-on-year.
Undervalued
The company’s latest PE is -45.14, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 134.76M shares, decreasing 3.46% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 352.52K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.36.

Analyst Rating

Based on 27 analysts
Buy
Current Rating
146.184
Target Price
-2.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Guardant Health Inc?

The TradingKey Stock Score provides a comprehensive assessment of Guardant Health Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Guardant Health Inc’s performance and outlook.

How do we generate the financial health score of Guardant Health Inc?

To generate the financial health score of Guardant Health Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Guardant Health Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Guardant Health Inc.

How do we generate the company valuation score of Guardant Health Inc?

To generate the company valuation score of Guardant Health Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Guardant Health Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Guardant Health Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Guardant Health Inc.

How do we generate the earnings forecast score of Guardant Health Inc?

To calculate the earnings forecast score of Guardant Health Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Guardant Health Inc’s future.

How do we generate the price momentum score of Guardant Health Inc?

When generating the price momentum score for Guardant Health Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Guardant Health Inc’s prices. A higher score indicates a more stable short-term price trend for Guardant Health Inc.

How do we generate the institutional confidence score of Guardant Health Inc?

To generate the institutional confidence score of Guardant Health Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Guardant Health Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Guardant Health Inc.

How do we generate the risk management score of Guardant Health Inc?

To assess the risk management score of Guardant Health Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Guardant Health Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Guardant Health Inc.
KeyAI